Health Care Delivery

The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."

Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.

A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.

A CHOP neonatologist explains how misinformation fuels vitamin K shot refusals and how public health messaging can meet parents where they are.

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

AI, patient voice in pathways, and caregiver support are shaping community oncology, AON leaders said at Patient-Centered Oncology Care.

Jeffery A. Goad, PharmD, MPH, of Chapman University explains why pharmacists are trusted, accessible sources for COVID-19 vaccine questions.

Build scalable obesity care with multidisciplinary teams, clear triage, and monitoring protocols; address GLP-1 gaps, Medicare access and price barriers, including oral GLP-1.

CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.

Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC, discusses how data builds payer trust, reduces prior authorization, and expands access in community oncology.

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

Without a functioning ACIP, Jeffery Goad, PharmD, MPH, explains who now guides COVID-19 vaccine use and how HMOs can stock vaccines.

Policy mandates and low-burden trial designs are key to equitable stem cell transplant access, explains Karilyn Larkin, MD.

As US measles cases top 3600, Christina Madison, PharmD, explains how pharmacists can counter vaccine misinformation and rebuild trust.

FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.

Novel combinations may improve survival in Richter transformation, a hard-to-treat condition, says Adam Kittai, MD, of Perlmutter Cancer Center.

Mayo Clinic's Scott Soefje, PharmD, MBA, explains how logistics, contracts, and cost shape access to new cancer drugs and high-cost drug reviews.

Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.

Caregiver shortages limit access to transplant, CAR T, and bispecific therapies, and no system offers replacement support, says Duke's Thomas LeBlanc, MD, MA.

North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.

Gay and bisexual men make up 79.8% of new HIV diagnoses; Christina Madison, PharmD, on why trusted messengers matter.

Kevin Astle, PharmD, on how pharmacies can reach young men unaware of their HIV status and why step therapy limits PrEP.

In part 2, Christine Pfaff, RPh, MBA, explores reimbursement gaps, new payment models, and payer partnerships needed to expand cellular therapy access.

Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.

AI could ease oncology's drug development "traffic jam," while biomarker subsetting drives more personalized cancer care, David Spigel, MD, says.

In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.

Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.

NCCN concordance won't ensure coverage; OAB risk tied to income; 91% offer bispecifics; ruxolitinib spend hits $49.6M; TALK SAFE Act aids telepsychiatry.

Community oncology faces high costs and staffing hurdles for trials; Lucio N. Gordan, MD, urges pragmatic designs matching real-world patients.